China National Medicines Corp Ltd Cash Flow-to-Debt Ratio
China National Medicines Corp Ltd cash flow-to-debt ratio. China National Medicines Corp Ltd (600511) has a Cash Flow-to-Debt Ratio of -0.04x as of September 2025, meaning its operating cash flow of CN¥-540.00 Million could theoretically repay 0% of its total liabilities (CN¥15.19 Billion) in one year. Check 600511 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of China National Medicines Corp Ltd (2001–2024)
Cash flow-to-debt ratio of China National Medicines Corp Ltd from 2001 to 2024. Historical debt coverage capacity for China National Medicines Corp Ltd across 24 annual periods. Check 600511 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
China National Medicines Corp Ltd Cash Flow-to-Debt Ratio by Year (2001–2024)
China National Medicines Corp Ltd cash flow-to-debt ratio by year from 2001 to 2024. Year-by-year debt coverage analysis for China National Medicines Corp Ltd. For the full cash flow conversion analysis, see 600511 cash flow metrics.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.10x | CN¥1.66 Billion | CN¥15.95 Billion | ▼ -43.1% |
| 2023 | 0.18x | CN¥2.73 Billion | CN¥14.92 Billion | ▲ +4.9% |
| 2022 | 0.17x | CN¥2.40 Billion | CN¥13.75 Billion | ▲ +16.8% |
| 2021 | 0.15x | CN¥1.96 Billion | CN¥13.12 Billion | ▲ +35.4% |
| 2020 | 0.11x | CN¥1.30 Billion | CN¥11.81 Billion | ▼ -25.3% |
| 2019 | 0.15x | CN¥1.78 Billion | CN¥12.03 Billion | ▲ +63.9% |
| 2018 | 0.09x | CN¥981.65 Million | CN¥10.90 Billion | ▼ -10.2% |
| 2017 | 0.10x | CN¥1.07 Billion | CN¥10.71 Billion | ▼ -42.6% |
| 2016 | 0.17x | CN¥591.25 Million | CN¥3.38 Billion | ▲ +20.7% |
| 2015 | 0.14x | CN¥440.29 Million | CN¥3.04 Billion | ▲ +95.5% |
| 2014 | 0.07x | CN¥218.94 Million | CN¥2.96 Billion | ▲ +15.1% |
| 2013 | 0.06x | CN¥185.56 Million | CN¥2.88 Billion | ▼ -6.9% |
| 2012 | 0.07x | CN¥185.87 Million | CN¥2.69 Billion | ▲ +137.6% |
| 2011 | -0.18x | CN¥-370.56 Million | CN¥2.02 Billion | ▼ -218.2% |
| 2010 | 0.16x | CN¥318.21 Million | CN¥2.05 Billion | ▲ +3.0% |
| 2009 | 0.15x | CN¥255.18 Million | CN¥1.69 Billion | ▼ -21.7% |
| 2008 | 0.19x | CN¥217.10 Million | CN¥1.13 Billion | ▲ +197.7% |
| 2007 | 0.06x | CN¥79.48 Million | CN¥1.23 Billion | ▼ -59.0% |
| 2006 | 0.16x | CN¥121.50 Million | CN¥771.05 Million | ▲ +29.8% |
| 2005 | 0.12x | CN¥92.20 Million | CN¥759.27 Million | ▲ +74.0% |
| 2004 | 0.07x | CN¥49.18 Million | CN¥704.48 Million | ▲ +8123.0% |
| 2003 | 0.00x | CN¥526.15K | CN¥619.80 Million | ▼ -97.7% |
| 2002 | 0.04x | CN¥15.19 Million | CN¥408.75 Million | ▲ +194.8% |
| 2001 | -0.04x | CN¥-11.80 Million | CN¥300.99 Million | — |